FASN and primary cutaneous T-cell non-Hodgkin lymphoma: Overall, in this study, we confirmed the overexpression of FASN in CTCL, preliminarily disclosed its oncogenic role in CTCL, and proposed that the combination of FASN and SREBP inhibitors could be a potential therapy for CTCL patients.